Allergies, Antibody, RNA and Vaccination - Clinical Research Informer

HIV vaccines suffer setbacks but new approaches could turn the tide

Pharmaceutical Technology

FEBRUARY 3, 2023

Only a few weeks into the new year, the prospect of getting a successful advanced HIV vaccine shrank after the discontinuation of yet another late-stage trial. On January 18, Janssen, a Johnson & Johnson (J&J) subsidiary, stated that its vaccine was not effective in preventing HIV infections.

Vaccination

Vaccination Vaccine Antibody Trials

Gritstone bio supports mRNA Covid-19 vaccine plans with Phase I publication

Pharmaceutical Technology

JUNE 8, 2023

Gritstone bio has reported interim results from an ongoing Phase 1 study evaluating the company’s self-amplifying mRNA (samRNA) vaccine as a boost against Covid-19 (CORAL-BOOST). The Phase I CORAL-BOOST dose-escalation trial (NCT05148962) evaluated Gritstone’s samRNA candidate (GRT-R910) in previously vaccinated healthy older adults.

Vaccination

Vaccination Vaccine Immune Response Allergies

Moderna’s Covid-19 shot gets Australian TGA provisional approval for kids

Pharmaceutical Technology

JULY 18, 2022

Moderna has received provisional registration from the Australian Therapeutic Goods Administration (TGA) for its messenger RNA (mRNA) Covid-19 vaccine, Spikevax, for kids aged six months to five years. The 25µg two-dose vaccine regimen is indicated for active immunisation for the prevention of Covid-19.

Vaccination

Vaccination Vaccine Gene Therapy Antibody

What Challenges Is the Vaccine Industry Facing When Dealing with the Flu and COVID-19?

XTalks

OCTOBER 26, 2023

The best way to prevent the flu is by getting vaccinated every year. The CDC and the World Health Organization (WHO) recommend annual flu vaccination for most people, especially those at high risk of serious complications, like pregnant women, elderly individuals, children and people with certain chronic health conditions.

Vaccination

Vaccination Vaccine RNA Manufacturing

This week in drug discovery (8-12 January)

Drug Discovery World

JANUARY 12, 2024

Study reveals therapeutic potential of mRNA in rare diseases Researchers have used messenger RNA (mRNA) to create an effective therapy for a rare liver disease in preclinical studies, demonstrating the technology’s potential therapeutic use in people.

Drugs

Drugs Immune Response Allergies Bacteria

Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine

The Pharma Data

NOVEMBER 16, 2020

November 16, 2020 — An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. The interim analysis comprised 95 cases of symptomatic COVID-19 among volunteers.

Clinical Trials

Clinical Trials Clinical Trials Vaccination Vaccine

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19

Pfizer

NOVEMBER 2, 2022

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19. Wed, 11/02/2022 - 15:44. Thursday, November 03, 2022 - 06:45am. Ugur Sahin, M.D.,

Vaccination

Vaccination Vaccine Clinical Trials Clinical Trials

World AIDS Day 2023: New and Promising Treatments for HIV/AIDS

XTalks

NOVEMBER 30, 2023

Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable. Promising HIV Vaccines in Clinical Trials Advancements in preventable therapeutic options for HIV are currently in progress. percent in the placebo group.

FDA Approval

FDA Approval Gene Therapy Clinical Trials Clinical Trials

Switzerland Exercises Increased Option for 7.5 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

The Pharma Data

DECEMBER 8, 2020

Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the Swiss Federal Government has increased its confirmed order commitment from 4.5 .–(BUSINESS WIRE)–Dec. 8, 2020– Moderna, Inc.,

Vaccination

Vaccination Vaccine Manufacturing Containment

Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel

The Pharma Data

JANUARY 4, 2021

Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that Israel’s Ministry of Health (MOH) has given authorization to import the COVID-19 Vaccine Moderna in Israel. The MOH has secured 6 million doses of the COVID-19 Vaccine Moderna.

Vaccination

Vaccination Vaccine Medicine Containment

Sanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issue

pharmaphorum

APRIL 28, 2021

The RNA interference (RNAi) drug is designed to treat haemophilia A and B patients by suppressing antithrombin (AT), a protein that inhibits blood clotting. The aim is to increase the generation of thrombin – a major component of the clotting cascade – and normalise clot formation. rise to €915 million.

Drugs

Drugs Sales Allergies RNA

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

XTalks

DECEMBER 24, 2020

From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. For example, investment in mRNA vaccines and viral vectors came well before January, many years before it.

Life Science

Life Science Vaccination Vaccine Gene

COVID-19 Pandemic Coverage

XTalks

SEPTEMBER 14, 2020

“Vaccine Nationalism” Could Prove the Undoing of COVID-19 Containment. Tension is mounting as nations big and small jockey around industry to ensure they are first in line to access a vaccine, should one prove to be successful against COVID-19. Moderna’s COVID-19 Vaccine. The price of that prize is incalculable.

Vaccination

Vaccination Vaccine Antibody Life Science

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. Pfizer’s Top 5 Best-Selling Drugs of 2022: 1) Comirnaty Comirnaty is an mRNA-based vaccine indicated for the prevention of COVID-19. billion in 2022. for a pediatric dose.

Sales

Sales Manufacturing FDA Approval Life Science

Clinical Research Informer

HIV vaccines suffer setbacks but new approaches could turn the tide

Gritstone bio supports mRNA Covid-19 vaccine plans with Phase I publication

Trending Sources

Moderna’s Covid-19 shot gets Australian TGA provisional approval for kids

What Challenges Is the Vaccine Industry Facing When Dealing with the Flu and COVID-19?

This week in drug discovery (8-12 January)

Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine

Pfizer and BioNTech Initiate Phase 1 Study of Single Dose mRNA-Based Combination Vaccine Candidate for Influenza and COVID-19

World AIDS Day 2023: New and Promising Treatments for HIV/AIDS

Switzerland Exercises Increased Option for 7.5 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273)

Israeli Ministry of Health Authorizes COVID-19 Vaccine Moderna for Use in Israel

Sanofi eyes 2022 filing for haemophilia drug fitusiran, despite safety issue

2020 Year in Review: COVID-19, CRISPR and Immunotherapies Define the Year for the Life Sciences

COVID-19 Pandemic Coverage

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

Stay Connected